Emeritus Professor of Medicine and Boehringer Ingelheim Chair of Clinical Pharmacology. Consultant to FDA, NIH, pharmaceutical and medical device industries
Gastroenterology
Dr. James W. Freston, MD
|
|
Give Review
James Freston practices Gastroenterology. He went to medical school at University of Utah School of Medicine. He received awards:"Fellow (AGAF)", "Julius Freidenwald Medal for Outstanding Contributions to Gastroenterology", "Distinguished Alumnus Award", "Endowed Chair in Clinical Pharmacology", "Outstanding Organ System Professor", "Burroughs-Wellcome Scholar in Clinical Pharmacology", "Outstanding Professor Award", "Society of the Sigma Xi", "Alpha Omega Alpha", "Fellow", "Medal of Merit" and "Meritorious Service Medal". James W. Freston, MD is a published doctor. He published 101 publications, including: 'Acid-related disorders in the new millennium: European, Japanese and North American perspectives.'
Publications
- Clinical and histopathologic features of fluoroquinolone-induced liver injury.
- Presentation of the Julius M. Friedenwald Medal to David A. Peura, MD, AGAF.
- Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
- Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
- Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
- Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.
- Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
- Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
- The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis.
- Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
- Use of pH-impedance testing to evaluate patients with suspected extraesophageal manifestations of gastroesophageal reflux disease.
- Recurrent pneumonia from severe nonacid reflux: a case report and discussion.
- Proton pump inhibitors: effective first-line treatment for management of dyspepsia.
- Advancing patient care: integrating new data.
- Rating the severity of the medical consequences of drug-induced liver injury.
- Our new president-David a. Peura, MD.
- Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
- A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
- Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
- Review article: approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy?
- Do children with gastroesophageal reflux become adults with gastroesophageal reflux? What is the role of Acid suppression in children?
- Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
- Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.
- Motion - All patients with GERD should be offered once in a lifetime endoscopy: arguments against the motion.
- Lansoprazole for maintenance of remission of erosive oesophagitis.
- Antagonist: Should we eradicate Helicobacter pylori before long term antireflux therapy?
- Review article: role of proton pump inhibitors in non-H. pylori-related ulcers.
- Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
- Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
- Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers?
- Helicobacter pylori-negative peptic ulcers: frequency and implications for management.
- Rofecoxib and the risk of adverse upper gastrointestinal effects.
- Management of peptic ulcers: emerging issues.
- Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events.
- Decision-making in dyspepsia: controversies in primary and secondary care.
- Safety profile of Lansoprazole: the US clinical trial experience.
- Acid-related disorders in the new millennium: European, Japanese and North American perspectives.
- Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithr...
- What remaining questions regarding Helicobacter pylori and associated diseases should be addressed by future research? View from North America.
- Review and analysis of the effects of olestra, a dietary fat substitute, on gastrointestinal function and symptoms.
- Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective.
- Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori.
- Successful practice in a managed care environment: managing costs while managing care.
- The American Gastroenterological Association: second century of leadership.
- Shortening the time between availability of new medical information and its adoption in general practice.
- The rationale for continuous maintenance treatment of reflux esophagitis.
- Critical issues in the management of gastroesophageal reflux disease.
- Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis.
- Peptic ulcer disease in adolescence: changing concepts in the age of Helicobacter pylori.
- Omeprazole, hypergastrinemia, and gastric carcinoid tumors.
- Emerging strategies for managing peptic ulcer disease.
- Future prospects for proton pump inhibitors.
- Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy.
- The public policy plan of the American Gastroenterological Association.
- Overview of medical therapy of peptic ulcer disease.
- On-demand treatment for duodenal ulcers: has its time come?
- Peptic ulcers in the elderly: unique features and management.
- Seronegative arthritis associated with serological evidence of Yersinia infection in Australia.
- Mechanisms of relapse in peptic ulcer disease.
- The pathophysiological and pharmacological basis of peptic ulcer therapy.
- Evolving perspectives on parenteral H2-receptor antagonist therapy.
- Safety perspectives on parenteral H2-receptor antagonists.
- H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
- The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment.
- Dose-ranging in clinical trials: rationale and proposed use with placebo or positive controls.
- Chronic abdominal pain. Functional or organic?
- Membrane damage and the pathogenesis of cardiomyopathies.
- Upper gastrointestinal polyps in Gardner's syndrome.
- Cimetidine: II. Adverse reactions and patterns of use.
- Cimetidine. I. Developments, pharmacology, and efficacy.
- Gastrointestinal Polyposis: Syndromes and Genetic Mechanisms.
- Transport of organic anions into liver cells and bile.
- Cimetidine and granulocytopenia.
- Antidiarrhoeal agents and laxatives: changing concepts.
- Effect of nighttime anisotropine methyl bromide of duodenal ulcer healing and pain: a double-blind controlled trial.
- Malignant transformation of esophageal columnar epithelium.
- Cimetidine, antacid, and hospitalization in the treatment of benign gastric ulcer: a multicenter double blind study.
- Cimetidine in the treatment of gastric ulcer: review and commentary.
- Studies on the pathogenesis of diet-induced dog gallstones.
- A double-blind evaluation of the nocturnal antisecretory effects of anisotropine methylbromide in man. Dose response and duration of action studies.
- Bilirubin removal by hemoperfusion through carbon and by in vivo immobilized enzymes.
- The role of pharmacology in the education of health-care professionals (pharmacy).
- Absorption and biotransfomation of cholecalciferol in drug-induced osteomalacia.
- The influence of phenobarbital on biotransformation of 25-hydroxycholecalciferol.
- The effect of detergent treatment of the gastric mucosa on drug transport.
- Ménétrier's Disease. Serial morphological, secretory, and serological observations.
- Toward a bioartificial drug metabolizing system: gel immobilized liver cell microsomes.
- Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children.
- Esophageal columnar epithelial beta-galactosidase and beta-glucuronidase.
- Enzyme and ultrastructural characteristics of esophageal columnar epithelium.
- Traumatic intrahepatic rupture of an echinococcal cyst.
- Chemical structure of erythromycin and hepatotoxicity.
- Severe intrahepatic cholestasis due to thiabendazole.
- Intrahepatic artery aneurysm associated with hemobilia. A case report.
- Recurrent melanoma presenting with obstructive jaundice. Report of two cases.
- Hepatotoxicity due to pemoline. Report of two cases.
- Biliary mucous substances in dihydrocholesterol-induced cholelithiasis.
- Changes in the ultrastructure of gall bladder epithelium in rabbits with experimental gallstones.
- The aetiology of gallstones.
- Experimental cholelithiasis.
Schools
University of Utah
University Utah Hosps
Royal Free Hospital
Doctors Specialties
- Internal Medicine
- Gastroenterology
Accepted Insurances
Awards
- Fellow (AGAF)
- Julius Freidenwald Medal for Outstanding Contributions to Gastroenterology
- Distinguished Alumnus Award
- Endowed Chair in Clinical Pharmacology
- Outstanding Organ System Professor
- Burroughs-Wellcome Scholar in Clinical Pharmacology
- Outstanding Professor Award
- Society of the Sigma Xi
- Alpha Omega Alpha
- Fellow
- Medal of Merit
- Meritorious Service Medal
Education
-
University of Utah -
University of Utah School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Peter E. Bloom Jr., MD |
|
|
Dr. Thomas J. Devers, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Birk, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Salam F. Zakko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Petr Protiva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaclyn Cox, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas J. Zaccheo, MD
This Doctor is OpenDoctor Recommended.
|